Oxaliplatin Accord Healthcare Ireland

Oxaliplatin, the active ingredient in Oxaliplatin Accord Healthcare Ireland, is a platinum‑based chemotherapy presented as a solution for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based agent used in the treatment of cancers that involve the gastrointestinal tract and related metastatic disease.

- Colorectal cancer: improves survival when combined with fluorouracil and leucovorin in adjuvant and metastatic settings. - Gastric cancer: used as part of combination regimens for advanced disease. - Pancreatic cancer: contributes to response rates when added to multi‑drug protocols. - Ovarian cancer: employed in selected regimens for recurrent disease. - Esophageal cancer: used in combination chemotherapy for locally advanced tumours. - Small‑cell lung cancer: occasionally incorporated into experimental combination protocols.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: watery stools that may require supportive care. - Fatigue: generalized tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count increasing bleed risk. - Elevated liver enzymes: transient rise in ALT/AST.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm. - Persistent neurotoxicity: long‑lasting sensory deficits. - Myelosuppression: profound neutropenia or anemia. - Acute pulmonary toxicity: interstitial pneumonitis. - Renal impairment: acute kidney injury in susceptible patients. - Cardiotoxicity: rare arrhythmias or myocardial injury.

When handling Oxaliplatin, clinicians should consider several safety and monitoring measures.

- Renal function: assess baseline creatinine and adjust if impaired. - Hepatic function: monitor liver enzymes before each cycle. - Neuropathy risk: evaluate baseline peripheral sensation and adjust dose if neuropathy develops. - Hematologic status: check complete blood count prior to infusion. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Storage: Store below 25°C: keep in the original container, protect from light and moisture.

Oxaliplatin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use with high‑dose cisplatin or aminoglycosides may worsen kidney injury. - Anticoagulants: increased bleeding risk when combined with warfarin or direct oral anticoagulants.

Moderate Interactions (Monitor Closely): - Antiemetics: serotonin‑receptor antagonists may enhance serotonin syndrome risk. - CYP450 inducers: drugs such as rifampicin could alter oxidative metabolism of supportive agents. - Immunosuppressants: heightened infection risk when combined with high‑dose steroids. - Radiotherapy: concurrent treatment may amplify neuro‑toxic effects. - Herbal supplements: St John’s wort may affect plasma levels of concomitant supportive drugs.